Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 4/20 | 0.42 |
| ▸ | PPARA | Q07869 | 4/20 | 0.42 |
| ▸ | PPARG | P37231 | 3/20 | 0.42 |
| ▸ | CTSG | P08311 | 11/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CMA1 | P23946 | 10/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13189312 | 0.84 | PLA2G7 (0.52) | PLA2G7HTTSMN1; SMN2PPARDPPARA | |
| SCHEMBL20928543 | 0.81 | PLA2G7 (0.50) | PLA2G7HTTSMN1; SMN2PPARDPPARA | |
| SCHEMBL8575703 | 0.79 | HTT (0.45) | PLA2G7HTTSMN1; SMN2PPARDPPARA | |
| SCHEMBL11082167 | 0.79 | MAPT (0.50) | PLA2G7HTTSMN1; SMN2PPARDPPARA | |
| SCHEMBL11393835 | 0.77 | PLA2G7 (0.46) | PLA2G7HTTSMN1; SMN2PPARDPPARA | |
| SCHEMBL10237827 | 0.77 | PLA2G7 (0.54) | PLA2G7MEN1KMT2APOLBHSD17B10 | |
| SCHEMBL11089881 | 0.76 | RAB9A (0.50) | PLA2G7HTTSMN1; SMN2PPARDPPARA | |
| SCHEMBL10814849 | 0.75 | MEN1 (0.46) | PLA2G7HTTSMN1; SMN2PPARDPPARA | |
| SCHEMBL10813333 | 0.75 | MEN1 (0.46) | PLA2G7HTTSMN1; SMN2PPARDPPARA | |
| SCHEMBL2191993 | 0.75 | HTT (0.51) | HTTSMN1; SMN2PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070716-A1 | ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2021-03-11 | — | — | US | disclosed |
| US-10882828-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2021-01-05 | — | — | US | disclosed |
| US-20190119222-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2019-04-25 | — | — | US | disclosed |
| US-20160137613-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137613-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | PLA2G7 294/4885HTT 4528/4885SMN1; SMN2 4234/4885 |
| US-10882828-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | PLA2G7 259/4885HTT 4509/4885SMN1; SMN2 3917/4885 |
| US-20210070716-A1 | ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | PLA2G7 259/4885HTT 4509/4885SMN1; SMN2 3917/4885 |
| US-20190119222-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | PLA2G7 294/4885HTT 4528/4885SMN1; SMN2 4234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.